Filed
pursuant to Rule 424(b)(5)
(File No.
333-139224)
The
information in this preliminary prospectus supplement is not complete and may be
changed. This preliminary prospectus supplement is not an offer to
sell these securities, and it is not soliciting an offer to buy these securities
in any state where the offer or sale is not permitted.
Subject
to completion, dated August 11, 2008
PRELIMINARY
PROSPECTUS
SUPPLEMENT
TO PROSPECTUS DATED DECEMBER 20, 2006
14,423,077
Shares
Warrants
to purchase 5,010,058 Shares
Focus
Enhancements, Inc.
Common
Stock
We are
offering to certain investors up to 14,423,077 shares of our common stock, par
value $0.01 per share, and warrants to purchase up to 5,010,058 shares of our
common stock (and the shares of common stock issuable from time to time upon
exercise of those warrants). The common stock and warrants will be
sold in units, with each unit consisting of one share of common stock and a
warrant to purchase up to 0.35 shares of common stock at an exercise price of
$[ ] per share. The warrants are exercisable six months and one
day after their issuance. The shares of common stock and the warrants
are immediately separable and will be issued separately.
Our common
stock is listed on the Nasdaq Capital Market, under the ticker symbol
“FCSE.” The last reported sale price of our common stock on the
Nasdaq Capital Market on August 8, 2008 was $0.24 per share. The
aggregate market value of our outstanding voting and non-voting common equity
computed by reference using the average bid and asked price of such common
equity held by non-affiliates, as of June 23, 2008, was $24,825,145. The
amount of all securities offered pursuant to General Instruction I.B.6. of
Form S-3 during the prior 12 calendar month period that ends on, and
includes, the date of this prospectus is 14,423,077 shares of our common stock
and warrants to purchase 5,010,058 shares of common stock that we are offering
pursuant to this prospectus supplement and 2,034,092 shares of our common stock
underlying warrants previously offered by the Company.
Investing
in our common stock involves significant risks. See “Risk Factors”
beginning on page S-
4
of this prospectus
supplement and on page 4 of the accompanying prospectus.
____________________________________
|
|
|
|
Per Unit
|
|
|
|
|
|
Total
**
|
|
|
Price
to public*
|
|
$
|
$0.26
|
|
|
$3,750,000
|
|
Placement
Agent Fee
|
|
|
$0.02
|
|
|
$300,000
|
|
Proceeds,
before expenses, to us
|
|
$
|
$0.24
|
|
|
$3,450,000
|
|
____________________________________
|
|
*
Includes one share of common stock and a warrant to purchase 0.35 share of
common stock.
**Does
not reflect the proceeds from the exercise of warrants from this
offering.
We have
engaged First Montauk Securities Corp. to act as our placement agent in
connection with this offering. We estimate the total expenses of this
offering, excluding the placement agent fee, will be approximately
$40,000. Because there is no minimum offering amount required as a
condition to closing in this offering, the actual public offering amount,
placement agent fee and net proceeds to us, if any, in this offering are not
presently determinable and may be substantially less than the total maximum
offering amounts set forth above. We are not required to sell any
specific number or dollar amount or shares of common stock and warrants to
purchase common stock offered in this offering, but the placement agent will use
its best efforts to arrange for the sale of common stock and warrants to
purchase common stock offered.
Delivery
of the shares of common stock will be made on or about August [ ],
2008.
Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of
these securities or determined if this prospectus supplement or the accompanying
prospectus is truthful or complete. Any representation to the
contrary is a criminal offense.
The date
of this prospectus supplement is August [ ], 2008.
TABLE
OF CONTENTS
TABLE
OF CONTENTS
Prospectus
Supplement
|
|
|
|
|
|
|
Page
|
|
|
|
|
|
|
S-1
|
|
|
|
|
S-2
|
|
|
|
|
S-3
|
|
|
|
|
S-4
|
|
|
|
|
S-6
|
|
|
|
|
S-7
|
|
|
|
|
S-8
|
|
|
|
|
S-9
|
|
|
|
|
S-10
|
|
|
|
|
S-10
|
|
|
|
|
S-10
|
|
|
|
|
S-10
|
|
|
|
|
|
|
|
Prospectus
|
|
|
|
2
|
|
|
|
|
4
|
|
|
|
|
12
|
|
|
|
|
13
|
|
|
|
|
13
|
|
|
|
|
14
|
|
|
|
|
16
|
|
|
|
|
21
|
|
|
|
|
21
|
|
|
|
|
21
|
|
You
should rely only on the information contained in or incorporated by reference in
this prospectus supplement and the accompanying prospectus. We have
not authorized anyone to provide you with additional or different
information. We are not making an offer to sell these securities in
any jurisdiction where the offer or sale is not permitted. You should
not assume that the information contained in this prospectus supplement or the
accompanying prospectus is accurate as of any date other than the date of this
prospectus supplement or the accompanying prospectus, respectively, or that
information contained in any document incorporated or deemed to be incorporated
by reference is accurate as of any date other than the date of that
document.
This
document is in two parts. The first part is this prospectus
supplement, which describes the terms of this offering of our common stock and
warrants (and common stock underlying the warrants) and also adds to and updates
information contained in or incorporated by reference into the accompanying
prospectus. The second part is the accompanying prospectus, which
gives more information about us and the type of securities we may offer from
time to time under our shelf registration statement. The information
in this prospectus supplement updates information in the accompanying prospectus
and, to the extent it is inconsistent with the information in the accompanying
prospectus, replaces such information.
FORWARD-LOOKING STATEMENTS
This
prospectus supplement and the accompanying prospectus contain or incorporate by
reference certain forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933, as amended (the “Securities Act”), and Section
21E of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”),
and as such, may involve risks and uncertainties. Forward-looking
statements, which are based on certain assumptions and describe future plans,
strategies, and expectations, are generally identifiable by the use of words or
phrases such as “believe,” “plan,” “expect,” “intend,” “anticipate,” “estimate,”
“project,” “forecast,” “may increase,” “may fluctuate,” “may improve” and
similar expressions or future or conditional verbs such as “should,” “would,”
and “could.”
These
forward-looking statements relate to, among other things, expectations of the
business environment in which we operate, opportunities and expectations
regarding technologies, anticipated performance or contributions from new and
existing employees, proposed acquisitions, projections of future performance,
possible changes in laws and regulations, potential risks and benefits arising
from the implementation of our strategic and tactical plans, perceived
opportunities in the market, potential actions of significant stockholders and
statements regarding our mission and vision. Our actual results, performance,
and achievements may differ materially from the results, performance, and
achievements expressed or implied in such forward-looking statements due to a
wide range of factors. Factors that may cause such differences include, without
limitation, the availability of capital to fund our future cash needs, reliance
on major customers, history of operating losses, failure to integrate new
acquisitions, the actual amount of charges and transaction expenses associated
with the acquisitions, the ability to recognize expected synergies upon
acquisition and the related benefits envisioned by us, market acceptance of our
products, technological obsolescence, competition, component supply problems and
protection of proprietary information, as well as the accuracy of our internal
estimates of revenue and operating expense levels.
Each
forward looking statement should be read in conjunction with the “Risk Factors”
included in this supplement and the accompanying prospectus and incorporated by
reference herein, together with the “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” and the consolidated financial
statements and notes thereto, contained in our periodic reports filed with the
Securities Exchange Commission (“SEC”) and incorporated by reference herein. We
do not undertake, and specifically disclaim any obligation, to update any
forward-looking statements to reflect occurrences or unanticipated events or
circumstances after the date of such statements, except as required by
law.
PROSPECTUS SUPPLEMENT SUMMARY
The
following summary highlights information contained elsewhere or incorporated by
reference in this prospectus supplement and the accompanying
prospectus. It may not contain all of the information that is
important to you. Before making a decision to invest in our common
stock, you should read carefully this entire prospectus
supplement. This summary is qualified in its entirety by the more
detailed information and financial statements, including the notes thereto,
appearing elsewhere or incorporated by reference in this prospectus supplement
and the accompanying prospectus. Unless the context otherwise
requires, the terms ”Focus,” “Company,” “we,” “us” and “our” refer to Focus
Enhancements, Inc., a Delaware corporation, and our subsidiaries.
Focus
Enhancements, Inc.
Incorporated
in 1992, Focus Enhancements, Inc. and its subsidiaries develop and market
proprietary video technology in two areas: semiconductor and systems. Focus
markets its products globally to original equipment manufacturers (“OEMs”), and
dealers and distributors in the consumer and professional channels.
Semiconductor products include several series of Application Specific Standard
Products (“ASSPs”), which address the wireless video and data market using Ultra
Wideband (“UWB”) technology and the video convergence market. The UWB chipsets
are targeted for the wireless USB market while the video convergence chips are
deployed into portable media players, video conferencing systems, Internet TV,
media center and interactive TV applications. Focus’ systems products are
designed to provide solutions for the professional video production market
particularly for the video acquisition, media asset management and digital
signage markets. Focus markets its systems products primarily through the
professional channel. Focus production products include video scan converters,
video mixers, standard and high definition digital video disk recorders, MPEG
(Moving Picture Experts Group) recorders and file format conversion tools. Focus
media asset management systems products include network-based video servers,
long-duration program monitors and capture/playout components. Focus digital
signage and retail media solutions products include standard and high definition
MPEG players, servers.
General
Information
We were
incorporated in 1992. Our main address is 1370 Dell Avenue, Campbell,
California 95008 and our telephone number is (408) 866-8300. Our Web site
is located at http://www.Focusinfo.com. Information contained in our Web
site is not part of this prospectus.
THE OFFERING
|
|
|
Issuer
|
|
Focus
Enhancements, Inc.
|
|
|
Securities
Offered
|
|
14,423,077 shares
of common stock and warrants to purchase 5,010,058 shares of common stock.
(This prospectus supplement also relates to the offering of shares of
common stock issuable upon the exercise of the
warrants.)
|
|
|
Shares
of common stock to be outstanding immediately after this
offering
|
|
101,377,665 (includes
the 14,423,077 shares offered hereby)
|
|
|
|
Offering
Price
|
|
$0.26
|
|
|
|
Nasdaq
Capital Markets Symbol
|
|
FCSE
|
|
|
Use
of
Proceeds
|
|
We
will use the net proceeds from this offering for general corporate
purposes and working capital requirements.
|
|
|
|
Warrant
terms
|
|
The
warrants will be exercisable at a price of $[ ] per share of common
stock.
|
Except as
otherwise indicated herein, the information above and elsewhere in this
prospectus supplement regarding outstanding shares of our common stock is based
on 86,954,588 shares of common stock outstanding as of July 31, 2008 and
excludes the following shares of common stock:
·
|
5,512,529
shares of common stock issuable upon the exercise of stock options
outstanding as of July 31, 2008, with a weighted-average exercise price of
$1.05 per share;
|
·
|
32,703,748
shares of common stock issuable upon the exercise of warrants outstanding
as of July 31, 2008 with a weighted-average exercise price of $0.85 per
share;
|
·
|
2,235,034
shares of common stock reserved for future awards under our stock option
plans as of July 31, 2008;
|
·
|
3,161,000
shares of common stock issuable upon the conversion of 3,161 shares of
preferred stock as of July 31,
2008;
|
·
|
4,000,000
shares of common stock issuable upon the exercise of the warrants issued
hereunder.
|
RISK FACTORS
An
investment in our common stock and warrants involves various risks, including
those in the accompanying prospectus beginning on page 3. You should
carefully consider such risk factors, together with all of the information
contained in or incorporated by reference in this prospectus supplement, the
accompanying prospectus, our Annual Report on Form 10-K for the fiscal year
ended December 31, 2007, as amended, and our Quarterly Report on Form 10-Q for
the period ended March 31, 2008, which are incorporated by reference herein, in
determining whether to purchase our common stock and warrants. The
risks and uncertainties described in the accompanying prospectus are not the
only risks and uncertainties we face. Additional risks and
uncertainties not presently known to us or that we currently deem immaterial
also may impair our business operations. If any of the risks
described herein or in the accompanying prospectus actually occur, our business,
operating results, prospects and financial condition could be
harmed. This could cause the market price of our common stock to
decline and could cause you to lose all or part of your investment.
We
have a long history of operating losses.
As of
March 31, 2008, we had an accumulated deficit of $128.7 million. We
incurred net losses of $17.4 million, $15.9 million and $15.4 million for the
years ended December 31, 2007, 2006 and 2005, respectively, and we expect
to continue to incur net losses for the remainder of 2008. There can be no
assurance that we will ever become profitable. Additionally, our independent
registered public accounting firm has included an explanatory paragraph in its
report on our consolidated financial statements for the year ended
December 31, 2007 with respect to substantial doubt about our ability to
continue as a going concern. The consolidated financial statements do not
include any adjustments that might result from the outcome of that
uncertainty.
We
will need to raise additional capital, which may not be available when we need
it.
Historically,
we have met our short- and long-term cash needs through debt issuances, the sale
of common stock or other convertible securities in private placements, because
cash flow from operations has been insufficient to fund our
operations.
We
received net proceeds of $9.3 million from the issuance of secured notes and
warrants to a group of private investors in February 2008. We received net
proceeds of $6.2 million and $4.9 million from the issuances of common stock to
groups of private investors in February 2007 and September 2007,
respectively. We believe that we will need to raise additional amounts before
December 31, 2008 in addition to securities being sold hereby to continue
development and launch commercialization of our next generation UWB products.
The amount necessary will depend upon the results of ongoing UWB development
efforts and our Semiconductor and Systems businesses. Our future capital
requirements will remain dependent upon these and other factors, including cash
flow from operations, maintaining our gross margins at current or
increased levels, continued progress in research and development programs,
competing technological and market developments, and our ability to market our
new products successfully. There can be no assurance that additional equity or
debt financing, if required, will be available on acceptable terms or at all. If
we are unable to access equity or debt financings when we need it, our business
will be substantially harmed.
Our
future capital raising activities may dilute the ownership of our existing
stockholders.
We may
sell securities in the public and private equity markets if and when conditions
are favorable. Raising funds through the issuance of common stock will
dilute the ownership of our existing stockholders. Furthermore, we may
issue common stock, or securities convertible into or exercisable for our common
stock, at prices that represent a substantial discount to the market price of
our common stock, which could result in a decline in the trading price of our
common stock.
Currently
we do not meet the requirements to remain listed on the Nasdaq Capital
Market. If we are delisted, it could, among other things, decrease the
liquidity of our common stock, limit our ability to raise additional capital and
potentially accelerate the amounts due under our $20.8 million outstanding
principal amount of senior secured notes at the option of the holders of
such notes.
Our
common stock is traded on the Nasdaq Capital Market. There are various
quantitative listing requirements for a company to remain listed on the Nasdaq
Capital Market, including maintaining a minimum bid price of $1.00 per share of
common stock and stockholders’ equity of $2.5 million or market capitalization
of at least $35 million.
On June
16, 2008, the Company received a letter from The Nasdaq Stock Market (“Nasdaq”)
notifying the Company that it fails to comply with the market value of public
listed securities requirement for continued listing set forth in Marketplace
Rule 4310(c)(3)(B). Such rule requires that the Company’s market value not be
below $35,000,000 for ten consecutive trading days. According to Nasdaq, as of
June 13, 2008, the Company's listed securities market value was $30,214,960. The
Company had until July 16, 2008, to regain compliance with the
rule.
On August
15, 2007, Nasdaq notified us that for the previous 30 consecutive business days,
the bid price of our common stock had closed below the minimum $1.00 per share
price requirement for continued inclusion under Nasdaq Marketplace Rules. We
were initially given until February 11, 2008 to regain compliance. On February
12, 2008, we were then advised of an additional six months extension or until
August 11, 2008 to attain compliance with the Nasdaq Capital Market $1.00
minimum bid price rule.
We may take certain actions in order to
regain compliance with Nasdaq’s continued listing requirements. These
actions include, without limitation, a reverse stock split of our shares of
common stock. There can be no assurance, however, that such actions
will allow us to regain compliance with any of the Nasdaq’s continued listing
requirements. If we do not regain compliance with the continued
listing requirements within the allotted compliance period (including the
minimum bid price per share and the market capitalization requirement),
including any extensions that may be granted by Nasdaq, Nasdaq would notify us
that our common stock will be delisted from the Nasdaq Capital
Market.
If we are delisted from the Nasdaq
Capital Market, our shares may be quoted on the OTC Electronic Bulletin Board or
some other quotation medium, such as the pink sheets, depending on our ability
to meet the specific listing requirements of the specific quotation system and
market makers’ willingness to quote our shares on either of these mediums. As a
result, an investor might find it more difficult to trade, or to obtain accurate
price quotations for, such shares. Delisting might also reduce our ability
to raise capital as well as the visibility, liquidity, and price of our voting
common stock. If our common stock were not listed on the Nasdaq Capital Market
or another established automated over-the-counter trading market in the United
States, all amounts outstanding under our $20.8 million senior secured notes
would become due and payable at the option of the holders. We do not now have
such capital, and we may not have sufficient resources or access to additional
capital at the time such demand is made, to satisfy those note obligations at
the time they would become due, which would have a material adverse impact on
our financial condition and results of operations.
The
exercise price of a significant number of our outstanding warrants will adjust
downward in the event we issue equity securities or equity linked securities at
an effective price less than $0.80 per share. As a result, following
this offering, the anticipated proceeds we would receive from the exercise of
these warrants will be substantially reduced.
The exercise price of the warrants held
by our senior secured note holders will be adjusted without any change in the
number of securities purchasable under the warrants if the Company issues any
equity or equity linked securities in connection with a financing, the primary
purpose of which is to raise equity capital, at a net effective price to the
Company of less than $0.80 per share of common stock. If the Company makes
such an issuance, then the exercise price of the warrants issued and then
outstanding held by our senior secured note holders will be adjusted so that the
exercise price to purchase one share of common stock pursuant to the warrant
will be the net effective price received by the Company in the financing;
provided, however, that such adjustment to the exercise price may not result in
the exercise price of the warrant to be less than $0.35 per share. As of July
31, 2008, 27,372,965 shares are underlying these warrants. As a
result of this offering, the exercise price of the warrants held by our senior
secured note holders will be adjusted to $0.35 per share.
We have a significant number of
outstanding securities that will dilute existing stockholders upon conversion or
exercise.
At July
31, 2008, we had 3,161 shares of preferred stock issued and outstanding
32,703,748 warrants and 5,512,529 options outstanding which are all exercisable
for or convertible into shares of common stock. The 3,161 shares of preferred
stock are convertible into 3,161,000 shares of our voting common stock.
Furthermore, at July 31, 2008, 2,235,034 additional shares of common stock were
available for grant to our employees, officers, directors and consultants under
our current stock option and incentive plans. We also may issue additional
shares in acquisitions. Any additional grant of options under existing or future
plans or issuance of shares in connection with an acquisition will further
dilute existing stockholders.
USE OF PROCEEDS
We expect
that the net proceeds to us from the sale of our common stock (not including
proceeds that may be received upon exercise of the warrants) in this offering
after deducting estimated offering expenses, will be approximately
$3,410,000.
We
currently intend to use the net proceeds we receive from the sale of our common
stock in this offering for general corporate purposes, that may
include:
|
·
research and development
expenditures;
|
|
·
sales and marketing expenditures;
and
|
|
·
acquisitions of new businesses, technologies or products that we
believe complement or expand our
business.
|
Our
management will retain broad discretion as to the allocation of the net proceeds
from this offering. Pending the use of the net proceeds, we intend to
invest the net proceeds in interest-bearing, investment-grade and U.S.
government securities.
DILUTION
If you invest in our common stock and
warrants, your interest will be diluted to the extent of the difference between
the public offering price per share you pay in this offering and the net
tangible book value per share of our common stock immediately after this
offering.
Our net tangible book value of our
common stock as of March 31, 2008 was approximately ($13,944,000), or
approximately ($0.16) per share of common stock based upon 84,847,871 shares
outstanding. Net tangible book value per share is equal to our total
tangible assets, less our total liabilities, divided by the total number of
shares of our common stock outstanding as of March 31, 2008. After
giving effect to the sale by us of the 14,423,077 shares of our common stock and
warrants to purchase 5,010,058 shares of common stock in this offering at the
public offering price of $0.26 per unit, and our receipt of the net proceeds
from the sale of those securities (excluding any proceeds received upon exercise
of warrants), our as-adjusted net tangible book value would have been
approximately ($10,534,000), or approximately ($0.11) per share of common stock
based upon 99,270,948 shares outstanding. This represents an
immediate increase in net tangible book value of $0.05 per share to our existing
stockholders and an immediate dilution in net tangible book value of $0.37 per
share to new investors. The following table illustrates this
calculation on a per share basis:
Public
offering price per share
|
|
|
$0.26
|
Net
tangible book value per share as of March 31, 2008
|
|
|
($0.16)
|
Increase
per share attributable to offering
|
|
|
$0.05
|
Pro
forma net tangible book value per share after this
offering
|
|
|
($0.11)
|
Dilution
per share to new investors
|
|
|
($0.37)
|
The
foregoing calculations exclude the following, each stated as of March 31,
2008:
|
•
|
|
5,573,509
shares of common stock issuable upon the exercise of stock options with a
weighted-average exercise price of $1.14 per
share;
|
|
•
|
|
32,176,199
shares of common stock issuable upon the exercise of warrants with a
weighted-average exercise price of $0.88 per
share;
|
|
•
|
|
2,792,735
shares of common stock reserved for future awards under our stock option
plans;
|
|
•
|
|
3,161,000
shares of common stock issuable upon the conversion of 3,161 shares of
preferred stock;
|
|
•
|
|
5,010,058
shares of common stock issuable upon the exercise of the warrants issued
hereunder.
|
DESCRIPTION OF WARRANTS
Purchasers will receive warrants for
the purchase of our common stock at an initial exercise price equal to $[
] per share for each share of common stock they purchase in this
offering. Each warrant may be exercised at any time and from time to
time after six months and one day following the issuance date and for five years
after the date of grant.
Exercise
. Holders
of the warrants may exercise their warrants to purchase shares of our common
stock on or before the expiration date by delivering (i) an exercise
notice, appropriately completed and duly signed, and (ii) payment of the
exercise price for the number of shares with respect to which the warrant is
being exercised. Warrants may be exercised in whole or in part, but
only for full shares of common stock, and any portion of a warrant not exercised
prior to the expiration date shall be and become void and of no
value. We provide certain buy-in rights to a holder if we fail to
deliver the shares of common stock underlying the warrants by the fifth trading
day after the date on which delivery of such stock certificate is required by
the warrant. The buy-in rights apply if after such fifth trading day, but prior
to cure by us, the holder purchases (in an open market transaction or otherwise)
shares of our common stock to deliver in satisfaction of a sale by the holder of
the warrant shares that the holder anticipated receiving from us upon exercise
of the warrant. In this event, at the request of and in the holder’s
discretion, we will pay cash to the holder in an amount equal to the amount by
which the holder’s total purchase price (including brokerage commissions, if
any) for the shares of common stock so purchased exceeds the product of
(A) such number of shares of common stock as we were required to delivered
to the holder, times (B) the price at which the sell order giving rise to
such purchase obligation was executed, and at the option of the holder, either
reinstate the portion of the warrant and equivalent number of common stock to be
issued pursuant to the warrant for which such exercise was not honored or
deliver to the holder a certificate or certificates representing the shares of
common stock underlying the exercised warrant that would have been issued had we
timely complied with our exercise and delivery obligations.
In addition, the warrant holders are
entitled to a “cashless exercise” option if, at any time of exercise, there is
no effective registration statement registering the warrant
shares. This option entitles the warrant holder to elect to receive
fewer shares of common stock without paying the cash exercise
price. The number of shares to be issued would be determined by a
formula based on the total number of shares to which the warrant holder is
entitled, the market price of the common stock on the date of exercise and the
applicable exercise price of the warrants.
The shares of common stock issuable on
exercise of the warrants will be, when issued in accordance with the warrants,
duly and validly authorized, issued and fully paid and non-assessable. We will
authorize and reserve at least that number of shares of common stock equal to
the number of shares of common stock issuable upon exercise of all outstanding
warrants.
Fundamental Transaction
. If,
at any time while the warrant is outstanding, (1) we effect any merger or
consolidation with or into another person or entity after which our shareholders
as of immediately prior to the transaction own less than a majority of the
outstanding stock of the surviving entity, (2) we effect any sale of all or
substantially all of our property, assets or business in one or a series of
related transactions, or (3) we effect any reorganization or
reclassification of the common stock (in any such case, a
“Fundamental Transaction”), then the holder shall have the right thereafter to
receive, upon exercise of the warrant, the same amount and kind of securities,
cash or property as it would have been entitled to receive upon the occurrence
of such Fundamental Transaction if it had been, immediately prior to such
Fundamental Transaction, the holder of the number of warrant shares then
issuable upon exercise of the warrant (the “Alternate Consideration”). In the
case of any such Fundamental Transaction, the surviving entity or the
corporation purchasing or otherwise acquiring such assets shall expressly assume
the due and punctual performance of each and every covenant and condition of the
warrant, and the other obligations and liabilities under the
warrant.
Delivery of Certificates
.
Upon the holder’s exercise of a warrant, we will promptly, but in no event later
than five trading days after the exercise date, issue and deliver, or cause to
be issued and delivered, a certificate for the shares of common stock issuable
upon exercise of the warrant, free of restrictive legends unless there is no
effective registration statement covering the issuance of the shares of common
stock or the shares of common stock issuable upon exercise of the warrant are
not freely transferable without volume restrictions under the Securities
Act. Share certificates issued at times when there is not a then
effective registration statement covering the issuance of the underlying common
stock will include customary legends restricting transfer to the extent we
determine necessary to ensure our compliance with the applicable
laws.
Certain Adjustments
. The
exercise price and the number of shares of common stock purchasable upon the
exercise of the warrants are subject to adjustment upon the occurrence of
specific events, including stock dividends, stock splits, and combinations or
reclassifications of our common stock. Upon any such event, each holder will be
provided the right to receive, upon exercise of such warrant, in addition to the
number of shares of common stock issuable under the warrant, the same kind and
amount of securities, cash or other property as it would have been entitled to
receive upon the occurrence of such transaction, if the warrant had been
exercised immediately prior to such transaction.
Additional Provisions
. The
above summary of certain terms and provisions of the warrants is qualified in
its entirety by reference to the detailed provisions of the warrants, the form
of which will be filed as an exhibit to a current report on Form 8-K that will
be incorporated herein by reference. We are not required to issue fractional
shares upon the exercise of the warrants. No holders of the warrants will
possess any rights as a shareholder under those warrants until the holder
exercises those warrants. The warrants may be transferred independent of the
common stock they were issued with, on a form of assignment, subject to all
applicable laws.
PLAN OF DISTRIBUTION
We will enter into securities purchase
agreements directly with the investors in connection with this offering, and we
will only sell to investors who have entered into securities purchase
agreements. Assuming all of the purchase agreements are executed by
the investors as currently contemplated and subject to the terms and conditions
of the purchase agreements, the investors will agree to purchase, and we will
agree to sell, an aggregate of up to 14,423,077 shares of our common stock and
warrants to purchase up to 5,010,058 shares of common stock, as provided on the
cover of this prospectus supplement.
In connection with this offering, we
will use First Montauk Securities Corp. (the “Placement Agent”) as our placement
agent to introduce investors to us. The Placement Agent is not
purchasing or selling any shares by this prospectus supplement or accompanying
prospectus, nor is it required to arrange for the purchase or sale of any
specific number or dollar amount of shares, but it has agreed to use best
efforts to arrange for the sale of all 14,423,077 shares of our common stock and
warrants to purchase up to 5,010,058 shares of our common stock.
Such Placement Agent may be deemed to
be an underwriter within the meaning of Section 2(a)(11) of the Securities Act,
and any fees or commissions received by the Placement Agent and any profit
realized on the resale of the securities sold by the Placement Agent while
acting as principal might be deemed to be underwriting discounts or commissions
under the Securities Act. As underwriters, the Placement Agent would
be required to comply with the requirements of the Securities Act and the
Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities
Act and Rule 10b-5 and Regulation M under the Exchange Act. These rules and
regulations may limit the timing of purchases and sales of shares of common
stock and warrants by the Placement Agent. Under these rules and
regulations, the Placement Agent:
- may
not engage in any stabilization activity in connection with our securities;
and
-
not bid for or purchase any of our securities or attempt to induce any person to
purchase any of our securities, other than as permitted under the Exchange Act,
until it has completed its participation in the distribution.
On August [ ], 2008, we entered
into an amended and restated agreement with the Placement Agent pursuant to
which the Placement Agent agreed to introduce us to one or more investors in
connection with this offering. Pursuant to the agreement, we will pay
the Placement Agent a cash fee equal to 8% of the cash proceeds we receive from
investors introduced to us by the Placement Agent. Pursuant to this
agreement, we have agreed to indemnify the Placement Agent against certain
liabilities under the Securities Act.
The
Placement Agent (or its associated) persons held, prior to the date of this
Prospectus Supplement, an aggregate of 140,683 common stock warrants which were
received in connection with a private placement completed in October 2005,
pursuant to which the Placement Agent served as placement agent for the
Company. The 140,683 warrants held by the Placement Agent (and its
associated persons) expire in October 2010.
The
agreement entered with the Placement Agent will be included as an exhibit to a
Current Report on Form 8-K that we will file with the SEC and that will be
incorporated by reference into the registration statement of which this
prospectus supplement forms a part.
The
shares of common stock sold in this offering will be listed on the Nasdaq
Capital Market. We expect that the shares of common stock will be
delivered directly through the transfer agent or in book-entry form through the
Depository Trust Company, New York, New York. The warrants will be
issued in certificated form. We expect to deliver the shares of our
common stock and warrants being offered pursuant to this prospectus supplement
on or about August [ ], 2008.
The
expenses directly related to this offering (exclusive of fees payable to the
Placement Agent) are estimated to be approximately $40,000 and will be paid by
us. Expenses of the offering include our legal and accounting fees,
printing expenses, transfer agent fees, Nasdaq Capital Market listing fees and
miscellaneous fees.
The
validity of our securities offered in this prospectus supplement and
accompanying prospectus will be passed upon for us by Manatt, Phelps &
Phillips, LLP, Palo Alto, California.
EXPERTS
The
consolidated financial statements incorporated in this prospectus by reference
to the Annual Report on Form 10-K for the year ended December 31, 2007, have
been so incorporated in reliance on the report (which contains an explanatory
paragraph relating to the Company’s ability to continue as a going concern as
described in Note 2 to the consolidated financial statements) of Burr, Pilger
& Mayer LLP, an independent registered public accounting firm, given on the
authority of said firm as experts in auditing and accounting.
WHERE YOU CAN FIND
MORE INFORMATION
We
file annual and quarterly reports, proxy statements and other information with
the SEC. You may read and copy any document we file at the SEC’s public
reference rooms in Washington, D.C., 100 F Street N.E., Washington D.C. 20549.
Please call the SEC at 1-800-SEC-0330 for further information on the public
reference rooms. Copies of these materials can be obtained at prescribed rates
from the Public Reference Section of the SEC at its principal office at 100 F
Street, N.E., Washington, D.C. 20549. Our SEC filings are also available to the
public from the SEC’s Website at “http://www.sec.gov.” The
information on the SEC’s web site is not part of this prospectus supplement and
the accompanying prospectus, and any references to this web site or any other
web site are inactive textual references only.
This prospectus supplement and
accompanying prospectus provides you with a general description of the
securities being registered. This prospectus supplement and
accompanying prospectus are part of a registration statement that we have filed
with the SEC. To see more detail, you should read the exhibits and schedules
filed with our registration statement. You may obtain copies of the registration
statement and the exhibits and schedules to the registration statement as
described above.
INCORPORATION
OF
CERTAIN
INFORMATION BY
REFERENCE
The SEC permits us to “incorporate by
reference” the information contained in documents we file with the SEC, which
means that we can disclose important information to you by referring you to
those documents rather than by including them in this prospectus supplement and
the accompanying prospectus. Information that is incorporated by reference is
considered to be part of this prospectus supplement and the accompanying
prospectus and you should read it with the same care that you read this
prospectus supplement and the accompanying prospectus. Later information that we
file with the SEC will automatically update and supersede the information that
is either contained, or incorporated by reference, in this prospectus supplement
and the accompanying prospectus, and will be considered to be a part of this
prospectus supplement and the accompanying prospectus from the date those
documents are filed. We incorporate by reference the following documents we
filed with the SEC with the exception of those items deemed to be only furnished
with the SEC:
Our SEC Filings (File No.
1-11860)
|
|
Date of Filing
|
Annual
Report on Form 10-K for the year ended December 31, 2007
|
|
March
28, 2008
|
Annual
Report on Form 10-K/A for the year ended December 31, 2007
|
|
April
29, 2008
|
Current
Report on Form 8-K
|
|
February
15, 2008
|
Current
Report on Form 8-K
|
|
February
25, 2008
|
Current
Report on Form 8-K
|
|
March
6, 2008
|
Current
Report on Form 8-K
|
|
June
20, 2008
|
Current
Report on Form 8-K
|
|
July
1, 2008
|
Current
Report on Form 8-K
|
|
July
7, 2008
|
Current
Report on Form 8-K
|
|
July
21, 2008
|
Current
Report on Form 8-K
|
|
July
31, 2008
|
Quarterly
Report on Form 10-Q for the quarter ended March 31, 2008
|
|
May
15, 2008
|
We also incorporate by reference all
additional documents that we file with the SEC under the terms of
Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act that are made
between the date of this prospectus supplement and the termination of any
offering of securities offered by this prospectus supplement or the accompanying
prospectus. In no event, however, will any information that we furnish under
Item 2.02 or Item 7.01 of any Current Report on Form 8-K or other information
that we may from time to time furnish to the SEC (rather than file) be
incorporated by reference into, or otherwise become a part of, this
prospectus.
You may request a copy of any or all of
the documents incorporated by reference but not delivered with this prospectus
supplement and the accompanying prospectus, at no cost, by writing or
telephoning us at the following address:
Focus
Enhancements, Inc.
1370 Dell
Avenue
Campbell,
California 95008
Attention: Investor
Relations
Phone: (408)
866-8300
PROSPECTUS
$45,000,000
FOCUS
ENHANCEMENTS, INC.
By
this prospectus, we may offer, from time to time —
Common
Stock
Warrants
Units
We may
from time to time issue up to an aggregate of $45,000,000 of common stock,
warrants and units comprised of any or all of these securities in one or more
issuances. We may sell these securities directly to you, through
underwriters or through agents or dealers we select. This prospectus
describes the general manner in which our common stock, warrants and units may
be offered using this prospectus. We will provide you with specific terms
of the offerings in one or more supplements to this prospectus. If we use
agents, underwriters or dealers to sell the securities, we will name them and
describe their compensation in a prospectus supplement.
Our
common stock is listed on the NASDAQ Capital Market under the ticker symbol
“FCSE.” The last reported sale price of our common stock on the NASDAQ Capital
Market on December 4, 2006 was $1.41 per share.
Investing
in these securities involves significant risks. See “Risk Factors”
beginning on page 3 for information you should consider before buying our
securities. We urge you to read the information included and incorporated
by reference in this prospectus and any prospectus supplement carefully before
you invest.
Neither
the Securities and Exchange Commission nor any state securities commission has
approved or disapproved of these securities or passed upon the adequacy or
accuracy of this prospectus. Any representation to the contrary is a
criminal offense.
This
prospectus may not be used to consummate sales of securities unless it is
accompanied by a prospectus supplement.
The date
of this Prospectus is December 20, 2006.
TABLE OF CONTENTS
|
|
PAGE
|
|
|
|
|
|
2
|
|
|
|
|
|
4
|
|
|
|
|
|
12
|
|
|
|
|
|
13
|
|
|
|
|
|
13
|
|
|
|
|
|
14
|
|
|
|
|
|
16
|
|
|
|
|
|
21
|
|
|
|
|
|
21
|
|
|
|
|
|
21
|
You
should rely only on the information incorporated by reference or provided in
this prospectus or any applicable supplement. We have not authorized
anyone else to provide you with different information. You should assume
that the information contained in this prospectus and any applicable supplement
is accurate only as of their respective dates even though this prospectus may be
delivered or shares may be sold under this prospectus on a later date. We
are not making an offer of the common stock, warrants and units in any state
where the offer is not permitted.
The
following summary is qualified by more detailed information, including our
consolidated financial statements and related notes, included in this prospectus
and incorporated in this prospectus by reference. You should carefully
consider the information set forth in this entire prospectus, including the
“Risk Factors” section, the applicable prospectus supplement for our securities
offered hereby and the other documents we refer to and incorporate by reference,
including but not limited to, the section entitled “Risk Factors” in our Annual
Report on Form 10-K for the fiscal year ended December 31, 2005 and in our other
filings with the Securities and Exchange Commission. Unless the context
otherwise requires, the terms “Focus,” “Company,” “we,” “us” and “our” refer to
Focus Enhancements, Inc., a Delaware corporation, and our
subsidiaries.
This
prospectus is part of a registration statement that we filed with the Securities
and Exchange Commission, or SEC, using a “shelf” registration process. Under
this shelf registration process, from time to time, we may offer up to
$45,000,000 of common stock, warrants and units comprised of any or all of these
securities in one or more offerings and in any combination. This prospectus
provides you with a general description of the common stock, warrants and units
we may offer. Each time we offer shares of common stock, warrants and units, you
will be provided with a prospectus supplement that will describe specific
information about the terms of that offering. The prospectus supplement may also
add, update or change information contained in this prospectus. This prospectus,
together with the prospectus supplements, will include all material information
relating to that offering. You should read both this prospectus and any
prospectus supplement, including the Risk Factors, together with the additional
information described under the heading “Where You Can Find More
Information.”
Focus
Enhancements, Inc.
We are a
technology company that develops and markets proprietary video technology in two
areas: semiconductors and systems. We market our products globally to original
equipment manufacturers (“OEMs”), and dealers and distributors in the consumer
and professional channels. Semiconductor products include several series of
Application Specific Integrated Circuits (“ASICs”), which process digital and
analog video to be used with televisions, computer motherboards, graphics cards,
video conferencing systems, Internet TV, media center and interactive TV
applications. In addition, o ur semiconductor group is currently developing a
wireless integrated circuit (“IC”) chip set based on the WiMedia Ultra Wideband
(“UWB”) standard, designed to be compatible with Wireless USB, and used in
personal computer, consumer electronics (“CE”), and mobile electronics
applications. Our systems products are designed to provide solutions in PC-to-TV
scan conversion, video presentation, digital-video (“DV”) conversion, video
production and home theater markets. We market these systems products through
both consumer and professional channels. Our consumer and production systems
products include video scan converters, video mixers, DV and high definition
digital video disk recorders, Moving Picture Experts Group (“MPEG”) recorders,
and file format conversion tools. Our digital asset management system products
include network-based video servers with video capture and play-out components.
Our digital signage and retail media solutions products include both standard
and high definition MPEG players, servers and associated control
software.
We were
incorporated in 1992. Our main address is 1370 Dell Avenue, Campbell,
California 95008 and our telephone number is (408) 866-8300. Our Web
site is located at http://www.Focusinfo.com. Information contained in our
Web site is not part of this prospectus.
The
Securities We May Offer
We may
offer up to $45,000,000 of common stock, warrants and units in one or more
offerings and in any combination. A prospectus supplement, which we will
provide each time we offer securities hereunder, will describe the specific
amounts, prices and terms of such securities.
We may
sell these securities to or through underwriters, dealers or agents or directly
to purchasers. We, as well as any agent acting on our behalf, reserve the
sole right to accept or reject in whole or in part any proposed purchase of
securities. Each prospectus supplement will set forth the names of any
underwriters, dealers or agents included in the sale of securities described in
that prospectus supplement and any applicable fee, commission or discount
arrangements with them.
Common
Stock
We may
offer shares of our common stock either alone or underlying other registered
securities convertible into our common stock. Holders of our common stock
are entitled to receive dividends subject to rights, if any, of preferred
stockholders, and debt holders.
Warrants
We may
issue warrants for the purchase of common stock. We may issue warrants
independently or together with other securities.
Units
We may
issue units comprised of common stock and warrants to purchase common
stock. We may issue units independently or together with other
securities.
You
should carefully consider the following risks relating to our business, our
common stock, warrants and units, together with the other information described
elsewhere in this prospectus before making an investment decision. If any
of the following risks actually occur, our business could be harmed, the trading
price of our common stock could decline, and you might lose all or part of your
investment. Additional risks not presently known to us or that we
currently believe are immaterial also may harm our business.
We
have a long history of operating losses.
As of
September 30, 2006, we had an accumulated deficit of $102.3 million. We incurred
net losses of $15.4 million, $11.0 million and $1.7 million for the years ended
December 31, 2005, 2004 and 2003, respectively and $12.9 million for the
first nine months of 2006. There can be no assurance that we will ever become
profitable. Additionally, our independent registered public accounting firm has
included an explanatory paragraph in its report on our consolidated financial
statements for the year ended December 31, 2005 with respect to substantial
doubt about our ability to continue as a going concern. The consolidated
financial statements incorporated by reference herein do not include any
adjustments that might result from the outcome of that uncertainty.
We
will likely need to raise additional capital.
Historically,
we have met our short- and long-term cash needs through debt issuances and the
sale of common stock in private placements, because cash flow from operations
has been insufficient to fund our operations. Set forth below is information
regarding net proceeds received through private placements of our common stock
and exercise of stock options and warrants in 2005, 2004 and 2003:
(In thousands)
|
|
Private Placements
of Common Stock
|
|
Exercise of Stock
Options and Warrants
|
|
|
|
|
|
|
|
2005
|
|
$
|
4,531
|
|
$
|
152
|
|
2004
|
|
$
|
10,741
|
|
$
|
192
|
|
2003
|
|
$
|
1,920
|
|
$
|
3,437
|
|
We
received gross proceeds of $10,000,000 from the issuance of senior secured
convertible notes to a group of private investors in January 2006. While we
believe that these funds, along with the cash flow generated by our expanding
Systems business, should be adequate to enable us to complete our UWB
engineering development and launch commercialization of UWB products, depending
upon the results and timing of our UWB initiative and the profitability of our
Systems business, we will likely need to raise further capital in 2007. Future
capital requirements will depend on many factors, including cash flow from
operations, continued progress in research and development programs, competing
technological and market developments, and our ability to market our products
successfully. There can be no assurance that additional equity or debt
financing, if required, will be available on acceptable terms or at all.
Moreover, any equity financing or convertible debt financing would result in
dilution to our existing stockholders and could have a negative effect on the
market price of our common stock.
From
November 2005 to early May 2006 and late May 2006 to mid July 2006, our common
stock did not meet the minimum bid price requirement to remain listed on the
NASDAQ Capital Market. If we were to be delisted, it could make trading in our
stock more difficult and our $10.4 million outstanding principal amount of
convertible notes would be deemed payable at the option of the
holders
Our
voting common stock is traded on the NASDAQ Capital Market. There are various
quantitative listing requirements for a company to remain listed on the NASDAQ
Capital Market, including maintaining a minimum bid price of $1.00 per share of
common stock and maintaining stockholders’ equity
of $2.5
million. On June 27, 2006, the NASDAQ Stock Market notified us that for the
previous 30 consecutive business days, the bid price of our common stock had
closed below the minimum $1.00 per share price requirement for continued
inclusion under NASDAQ Marketplace Rules. We were given until December 26, 2006
to regain compliance with the NASDAQ Capital Market $1.00 minimum bid price
rule. On July 28, 2006, we received notification from the NASDAQ Stock Market
that we had regained compliance and the matter was closed.
At
September 30, 2006, we had total stockholders’ equity of $5.9 million. To the
extent we incur net losses and do not raise additional capital, our
stockholders’ equity will be reduced. If the minimum bid price of our
common stock were to close below $1.00 for 30 consecutive days, we would likely
again receive notification from the NASDAQ Capital Market that we were not in
compliance with the $1.00 minimum bid price rule. If we do not regain compliance
within the allotted compliance period, including any extensions that may be
granted by the NASDAQ Capital Market, the NASDAQ Capital Market would notify us
that our common stock would be delisted from the NASDAQ Capital Market,
eliminating the only established trading market for our shares. We would then be
entitled to appeal this determination to a NASDAQ Listing Qualifications Panel
and request a hearing.
In the
event we are delisted from the NASDAQ Capital Market, we would be forced to list
our shares on the OTC Electronic Bulletin Board or some other quotation medium,
such as the pink sheets, depending on our ability to meet the specific listing
requirements of those quotation systems. As a result, an investor might find it
more difficult to trade, or to obtain accurate price quotations for, such
shares. Delisting might also reduce the visibility, liquidity, and price of our
voting common stock. In the event our common stock was not listed on the NASDAQ
Capital Market or another established automated over-the-counter trading market
in the United States, all amounts outstanding under our $10.4 million senior
secured convertible notes would become due and payable at the option of the
holders.
We
are dependent upon a significant stockholder to meet our financing needs and
there can be no assurance that this stockholder will continue to provide
financing.
We have
relied upon the ability of Carl Berg, a director and significant owner of our
common stock, for interim financing needs. Mr. Berg has provided a personal
guarantee to Samsung Semiconductor Inc., our contracted ASIC manufacturer, to
secure our working capital requirements for ASIC purchase order fulfillment and
a personal guarantee to Greater Bay Bank, N.A. in connection with our $4.0
million accounts receivable-based line of credit facility and $2.5 million term
loan. In connection with these guarantees, Mr. Berg maintains a security
interest in all the Company’s assets, subject to the bank’s lien on our accounts
receivable, and subordinating that security interest in accounts receivable to
holders of our convertible debt as described below. There can be no assurances
that Mr. Berg will continue to provide such interim financing or personal
guarantees, should we need additional funds or increased credit facilities with
our vendors.
We
have a significant amount of convertible securities and equity instruments that
will dilute existing stockholders upon conversion or exercise.
At
November 30, 2006, we had 3,161 shares of preferred shares issued and
outstanding, 4,645,395 warrants and 5,535,577 options outstanding, and $10.4
million of convertible notes outstanding, which are all exercisable into shares
of common stock. The 3,161 shares of preferred stock are convertible into
3,161,000 shares of our voting common stock and the convertible notes are
convertible into 10,425,000 shares of common stock. Furthermore, at November 30,
2006, 2,956,326 additional shares of common stock were available for grant to
our employees, officers, directors and consultants under our current stock
option and incentive plans. We also may issue additional shares in acquisitions
and additional convertible notes as interest payments on our outstanding
convertible notes.
Any additional grant of options under
existing or future plans or issuance of shares in connection with an acquisition
or issuance of additional convertible notes will further dilute existing
stockholders.
Delays in
product development could adversely affect our market position or customer
relationships.
We
have experienced delays in product development in the past and may experience
similar delays in the future. Given the short product life cycles in the markets
for certain products, any delay or unanticipated difficulty associated with new
product introductions or product enhancements could cause us to lose customers
and damage our competitive position. Prior delays have resulted from
numerous factors, such as:
|
·
changing product
specifications;
|
|
·
the discontinuation of certain third party
components;
|
|
·
difficulties in hiring and retaining necessary
personnel;
|
|
·
difficulties in reallocating engineering resources and other
resource limitations;
|
|
·
difficulties with independent
contractors;
|
|
·
changing market or competitive product
requirements;
|
|
·
unanticipated engineering
complexity;
|
|
·
undetected errors or failures in software and hardware;
and
|
|
·
delays in the acceptance or shipment of products by
customers.
|
The
development of new, technologically advanced products, including our significant
investment in UWB, is a complex and uncertain process requiring high levels of
innovation and highly skilled engineering and development personnel, as well as
the accurate anticipation of technological and market trends. In order to
compete, we must be able to deliver products to customers that are highly
reliable, operate with the customer’s existing equipment, lower the customer’s
costs of acquisition, installation and maintenance, and provide an overall
cost-effective solution. We may not be able to identify, develop, manufacture,
market or support new or enhanced products successfully, if at all, or on a
timely basis. Further, our new products may not gain market acceptance or we may
not be able to respond effectively to product announcements by competitors,
technological changes or emerging industry standards. Our failure to respond
effectively to technological changes would significantly harm our business.
Finally, there can be no assurances we will be successful in these
efforts.
We
rely on certain vendors for a significant portion of our manufacturing. If these
vendors experience delays in the production and shipping of our products, this
would have an adverse effect on our results of operations.
At
September 30, 2006, approximately 85% of the components for our products are
manufactured on a turnkey basis by four vendors: BTW Inc., Furthertech Company
Ltd., Samsung Semiconductor Inc. and Veris Manufacturing. If these vendors
experience production or shipping problems for any reason, we in turn could
experience delays in the production and shipping of our products, which would
have an adverse effect on our results of operations.
A
significant portion of our semiconductor revenue is from products that are
designed for consumer goods that have seasonal sales.
A
significant portion of our semiconductor revenue is subject to risks associated
with the sales of certain end products through retail outlets that are seasonal,
with a majority of such sales occurring October through December. As a
result, our annual operating results with respect to sales of our
semiconductor
chips designed into newly introduced products depend, in large part, on sales
during the relatively brief holiday season.
We are dependent on our suppliers. If our suppliers experience
labor problems, supply shortages or product discontinuations, this would have an
adverse effect on our results of operations.
We
purchase all of our parts from outside suppliers and from time-to-time
experience delays in obtaining some components or peripheral devices.
Additionally, we are dependent on sole source suppliers for certain
components. There can be no assurance that labor problems, supply
shortages or product discontinuations will not occur in the future, which could
significantly increase the cost, or delay shipment, of our products, which in
turn could adversely affect our results of operations.
If
we fail to meet certain covenants required by our credit facilities, we may not
be able to draw down on such facilities and our ability to finance our
operations could be adversely affected
.
We have
access to a $4.0 million credit line under which we can borrow up to 90% of our
eligible outstanding accounts receivable and a $2.5 million term loan with the
same bank. The various agreements in connection with such credit line and term
loan require us to maintain certain covenants. At September 30, 2006, we were
not in compliance with the net loss covenant. On November 8, 2006, we received a
waiver from Greater Bay Bank with respect to compliance with this covenant. In
the event we again violate this covenant, or we violate any other covenants and
are not able to obtain a waiver, we will not be able to draw down on the line of
credit or term loan, and any amounts outstanding under such line of credit or
term loan may become immediately due and payable, either of which could have a
material adverse impact on our financial condition and results of
operation.
Furthermore,
the restrictions contained in the line of credit and term loan documents, as
well as the terms of other indebtedness we may incur from time-to-time, could
limit our ability to plan for or react to market conditions or meet capital
needs or otherwise restrict our activities or business plans. These restrictions
could also adversely affect our ability to finance our operations or other
capital needs, or to engage in other business activities that would be in our
interest.
Certain
events will result in our senior secured convertible notes becoming due and
payable prior to maturity or will require us to repurchase our senior secured
convertible notes prior to maturity, either of which would adversely affect our
ability to finance our operations.
The
provisions of our senior secured convertible notes, due January 1, 2011, provide
that if we, among other things: (i) default on any principal or interest payment
on our senior secured convertible notes; (ii) fail to comply with any of our
covenants in the documents governing the issuance of our senior secured
convertible notes; (iii) do not pay at final maturity (either at stated maturity
or upon acceleration) any of our other indebtedness with an aggregate principal
amount of $1,000,000, the outstanding principal and accrued interest on such
notes will become due and payable. In addition, our senior secured convertible
notes provide, that, upon the occurrence of any of the following events, the
holders of the notes will have the right to require us to repurchase any or all
of such notes at a purchase price equal to 101% of the principal amount of notes
to be repurchased plus accrued and unpaid interest: (i) failure of our common
stock to be traded on a national securities exchange, NASDAQ Stock Market or
another established automated over-the-counter trading market in the United
States or (ii) acquisition of more than 50% of our outstanding voting stock or
merger with another company if our then shareholders do not continue to own a
majority of our outstanding voting stock. At September 30, 2006, we owed $10.4
million under our senior secured convertible notes. Repayment of this amount
prior to stated maturity would adversely impact our ability to finance our
operations or other capital needs.
If
we are unable to renew or extend our existing line of credit or term loan when
each expires on its own terms, our ability to finance our operations could be
adversely affected
.
We have
access to a $2.5 million term loan and a $4.0 million credit line facility with
the same bank. Both these credit facilities expire on December 24, 2006. If
we are unable to renew the term loan or credit line on favorable terms upon the
expiration, we would be required to immediately pay all outstanding obligations
under such term loan and credit line. Repayment of the principal amounts and
interest due under these facilities could adversely affect our other capital
requirements, as well as our ability to finance our operations on an ongoing
basis.
We depend on a few customers for a high percentage of our
revenues, and the loss or failure to pay of any one of these customers could
result in a substantial decline in our revenues and profits.
For the
year ended December 31, 2005, our five largest customers in the aggregate
provided 26% of our total revenues and as of December 31, 2005, comprised
45% of our accounts receivable balance. For the nine months ended September 30,
2006, our five largest customers in the aggregate provided 54% of our total
revenues, and as of September 30, 2006, comprised 46% of our accounts receivable
balance. Sales to one customer accounted for 48% and 26% of our revenue in the
three and nine month periods ended September 30, 2006, respectively. We do not
have long-term contracts requiring any customer to purchase any minimum amount
of products. There can be no assurance that we will continue to receive orders
of the same magnitude as in the past from existing customers or will be able to
market our current or proposed products to new customers. The loss of any major
customer, the failure of any such identified customer to pay us, or to
discontinue issuance of additional purchase orders, would have a material
adverse effect on our revenues, results of operation, and business as a whole,
absent the timely replacement of the associated revenues and profit margins
associated with such business. Furthermore, many of our products are dependent
upon the overall success of our customers’ products, over which we often have no
control.
Our
quarterly financial results are subject to significant fluctuations, and if
actual revenues are less than projected revenues, we may be unable to reduce
expenses proportionately, and our operating results, cash flows and liquidity
would likely be adversely affected.
We have
been unable in the past to forecast accurately our operating expenses or
revenues. Revenues currently depend heavily on volatile customer purchasing
patterns. If actual revenues are less than projected revenues, we may be unable
to reduce expenses proportionately, and our operating results, cash flows and
liquidity would likely be adversely affected.
Our
markets are subject to rapid technological change, and to compete effectively,
we must continually introduce new products, requiring significant influx of
additional capital until our overall operations generate sufficient profit to
fund such products internally.
Many of
our markets are characterized by extensive research and development and rapid
technological change resulting in short product life cycles. Development by
others of new or improved products, processes or technologies may make our
products or proposed products obsolete or less competitive. We must devote
substantial efforts and financial resources to enhance our existing products and
to develop new products, including our significant investment in UWB technology.
To fund such ongoing research and development, we will require a significant
influx of additional capital. There can be no assurance that we will succeed
with these efforts. Failure to effectively develop such products, notably our
UWB technology, could have a material adverse effect on our financial condition
and results of operations.
We
may not be able to protect our proprietary technology or
information.
As of
September 30, 2006, we held five patents and four pending patent applications in
the United States. Certain of these patents have also been filed and issued in
countries outside the United States. We treat our technical data as confidential
and rely on internal non-disclosure safeguards, including confidentiality
agreements with employees, and on laws protecting trade secrets, to protect our
proprietary
information.
There can be no assurance that these measures will adequately protect the
confidentiality of our proprietary information or prove valuable in light of
future technological developments.
There can
be no assurance that third parties will not assert infringement claims against
us or that such assertions will not result in costly litigation or require us to
license intellectual proprietary rights from third parties. In addition, there
can be no assurance that any such licenses would be available on terms
acceptable to us, if at all.
If
we are unable to respond to rapid technological change in a timely manner, then
we may lose customers to our competitors.
To remain
competitive, we must continue to enhance and improve the responsiveness,
functionality and features of our products. Our industry is characterized by
rapid technological change, changes in user and customer requirements and
preferences and frequent new product and service introductions. If competitors
introduce products and services embodying new technologies, or if new industry
standards and practices emerge, then our existing
proprietary
technology and systems may become obsolete. Our future success will depend
on our ability to do the following:
|
·
both license and internally develop leading technologies useful in
our business;
|
|
·
enhance our existing
technologies;
|
|
·
develop new services and technology that address the increasingly
sophisticated and varied needs of our prospective customers;
and
|
|
·
respond to technological advances and emerging industry standards
and practices on a cost-effective and timely
basis.
|
To
develop our proprietary technology entails significant technical and business
risks. We may use new technologies ineffectively, or we may fail to adapt our
proprietary technology and transaction processing systems to customer
requirements or emerging industry standards. If we face material delays in
introducing new services, products and enhancements, then our customers may
forego the use of our services and use those of our competitors.
We typically operate without a
significant amount of backlog, which could have an adverse impact on our
operating results
.
We
typically operate with a small amount of backlog. Accordingly, we generally do
not have a material backlog of unfilled orders, and revenues in any quarter are
substantially dependent on orders booked in that quarter. Any significant
weakening in current customer demand would therefore have, and has had in the
past, an almost immediate adverse impact on our operating results.
Our
common stock price is volatile.
The
market price for our voting common stock is volatile and has fluctuated
significantly to date. For example, between June 1, 2006 and November 30, 2006,
the per share price has fluctuated between $0.83 and $1.85 per share, closing at
$1.41 on December 4, 2006. The trading price of our voting common stock is
likely to continue to be highly volatile and subject to wide fluctuations in
response to factors including the following:
|
·
actual or anticipated variations in our quarterly operating
results;
|
|
·
announcements of technological innovations or failures, new sales
formats or new products or services by us or our
competitors;
|
|
·
cyclical nature of consumer products using our
technology;
|
|
·
changes in financial estimates by us or securities
analysts;
|
|
·
changes in the economic performance and/or market valuations of
other multi-media, video scan
companies;
|
|
·
announcements by us of significant acquisitions, strategic
partnerships, joint ventures or capital
commitments;
|
|
·
additions or departures of key
personnel;
|
|
·
additions or losses of significant customers;
and
|
|
·
sales of common stock or dilutive issuance of other
securities.
|
In
addition, the securities markets have experienced extreme price and volume
fluctuations in recent times, and the market prices of the securities of
technology companies have been especially volatile. These broad market and
industry factors may adversely affect the market price of common stock,
regardless of actual operating performance. In the past, following periods of
volatility in the market price of stock, many companies have been the object of
securities class action litigation, including us. If we are
sued in a securities class action, then it could result in additional
substantial costs and a diversion of management’s attention and
resources.
We are
subject to various environmental laws and regulations that could impose
substantial costs upon us and may adversely affect our business.
Some of
our operations are subject to state, federal, and international laws governing
protection of the environment, human health and safety, and regulating the use
of certain chemical substances. We endeavor to comply with these environmental
laws, yet compliance with such laws could increase our operations and product
costs. Any violation of these laws can subject us to significant liability,
including fines and penalties, and prohibit sales of our products in one or more
states or countries, and result in a material adverse effect on our financial
condition.
Recent
environmental legislation within the European Union (EU) may increase our cost
of doing business internationally and impact our revenues from EU countries as
we comply with and implement these new requirements. The European Parliament has
enacted the Restriction on Use of Hazardous Substances Directive, or “RoHS
Directive,” which restricts the use of certain hazardous substances in
electrical and electronic equipment. We need to redesign products containing
hazardous substances regulated under the RoHS Directive to reduce or eliminate
regulated hazardous substances contained in our products. As an example, certain
of our products include lead, which is included in the list of restricted
substances.
As of
November 30, 2006, our semiconductor products and many of our system products
now comply with the RoHS Directive. However, due to the level of effort and cost
in redesigning products, certain system products will not be redesigned to
become RoHS compliant. Such decisions have been made based on the products
estimated remaining life and the products primary sales regions being located
outside the EU. For certain of our mixer and digital signage products, we
continue working towards compliance but do not expect to meet the requirements
of the RoHS Directive until March 31, 2007 and June 30, 2007, respectively. As a
result, we will be unable to sell these products into the EU market until such
compliance is achieved. These delays may have an adverse effect on our sales and
results of operations.
Any
acquisitions of companies or technologies by us may result in distraction of our
management and disruptions to our business.
We may
acquire or make investments in complementary businesses, technologies, services
or products if appropriate opportunities arise, as was the case in
February 2004 when we acquired the stock of COMO Computer and Motion GmbH
and in May 2004 when we acquired substantially all the assets of Visual
Circuits Corporation. From time-to-time, we may engage in discussions and
negotiations with companies regarding the possibility of acquiring or investing
in their businesses, products, services or technologies. We may not be able to
identify suitable acquisition or investment candidates in the future, or if we
do identify suitable candidates, we may not be able to make such acquisitions or
investments on commercially acceptable terms, if at all. If we acquire or invest
in another company, we could have difficulty assimilating that company’s
personnel, operations, technology or products and service offerings. In
addition, the key personnel of the acquired company may decide not to work for
us. These difficulties could disrupt our ongoing business, distract our
management and employees, increase our expenses and adversely affect the results
of operations. Furthermore, we may incur indebtedness or issue equity securities
to pay for any future acquisitions and/or pay for the legal, accounting or
finders fees typically associated with an acquisition. The issuance of equity
securities could be dilutive to our existing stockholders. In addition, the
accounting treatment for any acquisition transaction may result in significant
goodwill and intangible assets, which, if impaired, will negatively affect our
consolidated results of operations. The accounting treatment for any potential
acquisition may also result in a charge for in-process research and development
expense, as was the case with the acquisition of Visual Circuits Corporation,
which will negatively affect our consolidated results of
operations.
We
are exposed to potential risks from legislation requiring companies to evaluate
financial controls under Section 404 of the Sarbanes-Oxley Act of
2002.
Section 404
of the Sarbanes-Oxley Act of 2002 requires that we evaluate and report on our
system of internal controls. We will be required to meet the requirements of
Section 404 of the Sarbanes-Oxley Act by December 31, 2007. Compliance with the
requirements of Section 404 is expected to be expensive and time-consuming.
We estimate that we will spend approximately $650,000 to comply. If we fail to
complete this evaluation in a timely manner, or if our
independent registered public accounting firm cannot timely
attest to our evaluation, we could be subject to regulatory scrutiny and a loss
of public confidence in our internal controls. In addition, any failure to
implement required new or improved controls, or difficulties encountered in
their implementation, could harm our operating results or cause us to fail to
meet our reporting obligations.
Risks Related to Our
Industry
International
sales are subject to significant risk.
Our
revenues from outside the United States are subject to inherent risks related
thereto, including currency rate fluctuations, the general economic and
political conditions in each country. There can be no assurance that an economic
or currency crisis experienced in certain parts of the world will not reduce
demand for our products and therefore have a material adverse effect on our
revenue or operating results.
Our
businesses are very competitive.
The
computer peripheral and semiconductor markets are extremely competitive and are
characterized by significant price erosion over the life of a product. We
currently compete with other developers of video conversion products and with
video-graphic integrated circuit developers. Many of our competitors have
greater market recognition and greater financial, technical, marketing and human
resources. There can be no assurance that we will be able to compete
successfully against existing companies or new entrants to the
marketplace.
The video
production equipment and semiconductor markets are highly competitive and
characterized by rapid technological change, new product development and
obsolescence, evolving industry standards and significant price erosion over the
life of a product. Competition is fragmented with several hundred manufacturers
supplying a variety of products to this market. We anticipate increased
competition from both existing manufacturers and new market entrants. Increased
competition could result in price reductions, reduced margins and loss of market
share, any of which could materially and adversely affect our business,
financial condition and results of operations. There can be no assurance that we
will be able to compete successfully against current and future competitors in
these markets.
Often our
competitors have greater financial, technical, marketing, sales and customer
support resources, greater name recognition and larger installed customer bases
than we possess. In addition, some of our competitors also offer a wide variety
of product offerings which may confer a competitive advantage based upon their
ability either to bundle their equipment in certain large system sales or
combine products more cost effectively than we can offer.
WHERE
YOU CAN FIND MORE INFORMATION
We file
annual, quarterly and current reports, proxy statements and other information
with the SEC. You may read and copy materials that we have filed with the
SEC at the SEC’s public reference room located at 100 F. Street N.E.,
Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for
further information on the public reference room. Our SEC filings also are
available to the public on the SEC’s website at http://www.sec.gov. In addition,
our SEC filings are available to the public on our website
http://www.Focusinfo.com.
The SEC
allows us to “incorporate by reference” in this prospectus information we file
with it, which means that we can disclose important information to you by
referring you those documents. The information incorporated by reference
is an important part of this prospectus, and information that we file later with
the SEC and which is incorporated by reference will automatically update and
supersede information contained in this prospectus or in documents filed earlier
with the SEC. We incorporate by reference the documents listed below and
any future filings we make with the SEC under Sections 13(a), 13(c), 14, or
15(d) of the Securities Exchange Act of 1934, as amended, after the date of the
filing of our registration statement on Form S-3, including this prospectus,
until our offering is complete. However, we are not incorporating, in each
case, any documents or information deemed to have been furnished and not filed
in accordance with SEC rules.
These
documents are incorporated herein by reference as of their respective dates of
filing:
|
·
|
Our
Annual Report of Form 10-K for the year ended December 31, 2005, as filed
with the Commission on March 31,
2006;
|
|
·
|
Our Quarterly Report
on Form 10-Q for the quarterly period ended March 31, 2006, as filed with
the Commission on May 15, 2006;
|
|
·
|
Our
Quarterly Report on Form 10-Q for the quarterly period ended June 30,
2006, as filed with the Commission on August 14,
2006;
|
|
·
|
Our
Quarterly Report on Form 10-Q for the quarterly period ended September 30,
2006, as filed with the Commission on November 14,
2006;
|
|
·
|
Our
Current Reports on Form 8-K, as filed with the Commission on January 30,
2006, February 21, 2006, February 24, 2006, March 9, 2006, March 15, 2006,
April 25, 2006, May 11, 2006, May 15, 2006, June 30, 2006, July 13, 2006,
August 2, 2006, August 10, 2006, August 15, 2006, September 28, 2006,
October 5, 2006, November 9, 2006, and November 21, 2006;
and
|
|
·
|
The description of
our common stock contained in our registration statement on Form 8-A, as
filed with the Commission on April 5, 1993, including any amendments or
reports filed for the purpose of updating that
description.
|
Our
filings are available on our website at http://www.Focusinfo.com. Information
contained in or linked to our website is not a part of this prospectus.
You may also request a copy of these filings, at no cost, by writing or
telephoning us at:
Focus
Enhancements, Inc.
1370 Dell
Avenue
Campbell,
California 95008
(408)
866-8300
FORWARD-LOOKING
STATEMENTS
This
document contains “forward looking” information within the meaning of the
Section 27A of the Securities Act of 1933, as amended (the “Securities Act”),
and Section 21E of the Securities and Exchange Act of 1934, as amended (the
“Exchange Act”), and as such, may involve risks and uncertainties.
Forward-looking statements, which are based on certain assumptions and describe
future plans, strategies, and expectations, are generally identifiable by the
use of words or phrases such as “believe,” “plan,” “expect,” “intend,”
“anticipate,” “estimate,” “project,” “forecast,” “may increase,” “may
fluctuate,” “may improve” and similar expressions or future or conditional verbs
such as “should,” “would,” and “could.”
These
forward-looking statements relate to, among other things, expectations of the
business environment in which we operate, opportunities and expectations
regarding technologies, anticipated performance or contributions from new and
existing employees, proposed acquisitions, projections of future performance,
possible changes in laws and regulations, potential risks and benefits arising
from the implementation of our strategic and tactical plans, perceived
opportunities in the market, potential actions of significant stockholders and
statements regarding our mission and vision. Our actual results, performance,
and achievements may differ materially from the results, performance, and
achievements expressed or implied in such forward-looking statements due to a
wide range of factors. Factors that may cause such differences include, without
limitation, the availability of capital to fund our future cash needs, reliance
on major customers, history of operating losses, failure to integrate new
acquisitions, the actual amount of charges and transaction expenses associated
with the acquisitions, the ability to recognize expected synergies upon
acquisition and the related benefits envisioned by us, market acceptance of our
products, technological obsolescence, competition, component supply problems and
protection of proprietary information, as well as the accuracy of our internal
estimates of revenue and operating expense levels.
Each
forward looking statement should be read in conjunction with the “Risk Factors”
included in this prospectus and incorporated by reference herein, together with
the “Management’s Discussion and Analysis of
Financial
Condition and Results of Operations” and the consolidated financial statements
and notes thereto, contained in our periodic reports filed with the SEC and
incorporated by reference herein. We do not undertake, and specifically disclaim
any obligation, to update any forward-looking statements to reflect occurrences
or unanticipated events or circumstances after the date of such statements,
except as required by law.
Unless we
otherwise indicate in the applicable prospectus supplement, we currently expect
to use the net proceeds we receive from the sale of our common stock, warrants
and units comprised of any or all of these securities, for general corporate
purposes, that may include:
|
·
research and development
expenditures;
|
|
·
sales and marketing expenditures;
and
|
|
·
acquisitions of new businesses, technologies or products that we
believe complement or expand our
business.
|
Additional
information on the use of net proceeds from the sale of the common stock,
warrants and units comprised of any or all of these securities we offer under
this prospectus may be set forth in the prospectus supplement relating to the
specific offering. Pending the use of the net proceeds, we intend to invest the
net proceeds in interest-bearing, investment-grade and U.S government
securities.
We may
sell the securities offered through this prospectus (i) to or through
underwriters or dealers, (ii) directly to purchasers, including our affiliates,
(iii) through agents, or (iv) through a combination of any these methods. The
securities may be distributed at a fixed price or prices, which may be changed,
market prices prevailing at the time of sale, prices related to the prevailing
market prices, or negotiated prices. The prospectus supplement will include the
following information:
|
·
the terms of the offering;
|
|
·
the names of any underwriters or
agents;
|
|
·
the name or names of any managing underwriter or
underwriters;
|
|
·
the purchase price of the
securities;
|
|
·
the net proceeds from the sale of the
securities;
|
|
·
any delayed delivery
arrangements;
|
|
·
any underwriting discounts, commissions and other items
constituting underwriters’
compensation;
|
|
·
any initial public offering
price;
|
|
·
any discounts or concessions allowed or reallowed or paid to
dealers; and
|
|
·
any commissions paid to
agents.
|
Sale Through Underwriters or
Dealers
If
underwriters are used in the sale, the underwriters will acquire the securities
for their own account, including through underwriting, purchase, security
lending or repurchase agreements with us. The underwriters may resell the
securities from time to time in one or more transactions, including negotiated
transactions. Underwriters may sell the securities in order to facilitate
transactions in any of our other securities (described in this prospectus or
otherwise), including other public or private transactions and short sales.
Underwriters may offer securities to the public either through underwriting
syndicates represented by one or more managing underwriters or directly by one
or more firms acting as underwriters. Unless otherwise indicated in the
prospectus supplement, the obligations of the underwriters to purchase the
securities will be subject to certain conditions, and the underwriters will be
obligated to purchase all the offered securities if they purchase any of them.
The underwriters may change from time to time any initial public offering price
and any discounts or concessions allowed or reallowed or paid to
dealers.
If
dealers are used in the sale of securities offered through this prospectus, we
will sell the securities to them as principals. They may then resell those
securities to the public at varying prices determined by the dealers at the time
of resale. The prospectus supplement will include the names of the dealers and
the terms of the transaction.
Direct
Sales and Sales Through Agents
We may
sell the securities offered through this prospectus directly. In this case, no
underwriters or agents would be involved. Such securities may also be sold
through agents designated from time to time.
The
prospectus supplement will name any agent involved in the offer or sale of the
offered securities and will describe any commissions payable to the agent.
Unless otherwise indicated in the prospectus supplement, any agent will agree to
use its reasonable best efforts to solicit purchases for the period of its
appointment.
We may
sell the securities directly to institutional investors or others who may be
deemed to be underwriters within the meaning of the Securities Act with respect
to any sale of those securities. The terms of any such sales will be described
in the prospectus supplement.
Delayed
Delivery Contracts
If the
prospectus supplement indicates, we may authorize agents, underwriters or
dealers to solicit offers from certain types of institutions to purchase
securities at the public offering price under delayed delivery contracts. These
contracts would provide for payment and delivery on a specified date in the
future. The contracts would be subject only to those conditions described in the
prospectus supplement. The applicable prospectus supplement will describe the
commission payable for solicitation of those contracts.
Market
Making, Stabilization and Other Transactions
Unless
the applicable prospectus supplement states otherwise, each series of offered
securities will be a new issue and will have no established trading market. We
may elect to list any series of offered securities on an exchange. Any
underwriters that we use in the sale of offered securities may make a market in
such securities, but may discontinue such market making at any time without
notice. Therefore, we cannot assure you that the securities will have a liquid
trading market.
Any
underwriter may also engage in stabilizing transactions, syndicate covering
transactions and penalty bids in accordance with Rule 104 under the Exchange
Act. Stabilizing transactions involve bids to purchase the underlying security
in the open market for the purpose of pegging, fixing or maintaining the price
of the securities. Syndicate covering transactions involve purchases of the
securities in the open market after the distribution has been completed in order
to cover syndicate short positions.
Penalty
bids permit the underwriters to reclaim a selling concession from a syndicate
member when the securities originally sold by the syndicate member are purchased
in a syndicate covering transaction to cover syndicate short positions.
Stabilizing transactions, syndicate covering transactions and penalty bids may
cause the price of the securities to be higher than it would be in the absence
of the transactions. The underwriters may, if they commence these transactions,
discontinue them at any time.
Electronic
Auctions
We may
also make sales through the Internet or through other electronic means. Since we
may from time to time elect to offer securities directly to the public, with our
without the involvement of agents, underwriters or dealers, utilizing the
Internet (sometimes referred to as the “world wide web”) or other forms of
electronic bidding or ordering systems for the pricing and allocation of such
securities, you will want to pay particular attention to the description of that
system we will provide in a prospectus supplement.
Such
electronic system may allow bidders to directly participate, through electronic
access to an auction site, by submitting conditional offers to buy that are
subject to acceptance by us, and which may directly affect the price or other
terms and conditions at which such securities are sold. These bidding or
ordering systems may present to each bidder, on a so-called “real-time” basis,
relevant information to assist in making a bid, such as the clearing spread at
which the offering would be sold, based on the bids submitted, and whether a
bidder’s individual bids would be accepted, prorated or rejected. Of course,
many pricing methods can and may also be used.
Upon
completion of such an electronic auction process, securities will be allocated
based on prices bid, terms of bid or other factors. The final offering price at
which securities would be sold and the allocation of securities among bidders
would be based in whole or in part on the results of the Internet or other
electronic bidding process or auction.
General
Information
Agents,
underwriters, and dealers may be entitled, under agreements entered into with
us, to indemnification by us against certain liabilities, including liabilities
under the Securities Act. Our agents, underwriters, and dealers, or their
affiliates, may be customers of, engage in transactions with or perform services
for us, in the ordinary course of business.
DESCRIPTION OF SECURITIES
General
The
following description, together with the additional information included in any
applicable prospectus supplement and incorporated herein by reference,
summarizes the material terms of the common stock, warrants and units comprised
of any or all of these securities that we may offer under this prospectus. For
complete terms of our common stock, please refer to our second restated
certificate of incorporation, as amended, and our amended and restated bylaws,
which are incorporated by reference into the registration statement which
includes this prospectus. The terms of our common stock, warrants and units may
also be affected by the General Corporation Law of Delaware. We will also
include in the prospectus supplement information, where applicable, about
material United States federal income tax considerations relating to our common
stock, and the securities exchange, if any, on which our common stock is
listed.
Description of Our Common
Stock
We are
authorized to issue up to 150,000,000 shares of common stock, $0.01 par value
per share. As of November 30, 2006, 71,577,891 shares of common stock were
issued and outstanding and 10,425,000 shares of common stock are issuable upon
conversion of our outstanding convertible securities. All of the outstanding
capital stock is fully paid and non-assessable.
Holders
of common stock are entitled to one vote per share. All actions submitted to a
vote of stockholders are voted on by holders of common stock and holders of our
outstanding preferred stock voting together as a single class. Our charter
requires the affirmative vote of the holders of shares of voting stock
representing at least 75% of the voting power of all of the then outstanding
shares of capital stock entitled to vote generally in the election of directors,
voting together as a single class, to (1) reduce or eliminate the number of
authorized shares of our preferred stock or (2) amend, repeal or adopt certain
provisions of our charter regarding our common stock and preferred stock, the
perpetual existence of our company, the management of our company, the board of
directors, the liability of directors to our company and the indemnification of
our directors and officers. In addition, our charter requires the
affirmative vote of the holders of shares of voting stock representing at least
80% of the voting power of all of the then outstanding shares of capital stock
entitled to vote generally in the election of directors, voting together as a
single class, to adopt, amend or repeal any provision of the bylaws of our
company. Holders of
common stock are not entitled to
cumulative voting in the election of directors. Our Board of Directors is
divided into three classes, each serving staggered three-year terms. As a
result, one class of directors will be elected at each annual meeting of our
stockholders, with the other classes continuing for the remainder of their
respective terms. This provision in our charter may have the effect of delaying
or preventing changes in control or management.
Additionally,
we are subject to Section 203 of the Delaware General Corporation Law, an
anti-takeover law. In general, Section 203 prohibits a publicly held Delaware
corporation from engaging in a “business combination” with an “interested
stockholder” for a period of three years following the date the person became an
interested stockholder, unless, with exceptions, the business combination or the
transaction in which the person became an interested stockholder is approved in
a prescribed manner. Generally, a business combination includes a merger, asset
or stock sale, or other transaction resulting in a financial benefit to the
interested stockholder. Generally, an interested stockholder is a person who,
together with affiliates and associates, owns, or within three years prior to
the determination of interested stockholder status, did own, 15% or more of a
corporation’s voting stock. The existence of this provision can be expected to
have an anti-takeover effect with respect to transactions not approved in
advance by the board of directors, including discouraging attempts that might
result in a premium over the market price for the shares of common stock held by
stockholders.
Holders
of common stock are entitled to receive dividends in cash or in property on an
equal basis, if and when dividends are declared on the common stock by our board
of directors, subject to any preference in favor of outstanding shares of
preferred stock.
In the
event of liquidation of our company, all holders of common stock will
participate on an equal basis with each other in our net assets available for
distribution after payment of our liabilities and payment of any liquidation
preferences in favor of outstanding shares of preferred stock.
Holders
of common stock are not entitled to preemptive rights and the common stock is
not subject to redemption.
Preferred
Stock
The
rights of holders of common stock are subject to the rights of holders of any
preferred stock that we designate or have designated. The rights of
preferred stockholders may adversely affect the rights of the common
stockholders.
Our board
of directors has the ability to issue up to 3,000,000 shares of preferred stock
in one or more series, without stockholder approval. The board of
directors may designate for the series:
|
·
the number of shares and name of the
series,
|
|
·
the voting powers of the series, including the right to elect
directors, if any,
|
|
·
the dividend rights and preferences, if
any,
|
|
·
redemption terms, if any,
|
|
·
liquidation preferences and the amounts payable on liquidation or
dissolution, and
|
|
·
the terms upon which such series may be converted into any other
series or class of our stock, including the common stock and any other
terms that are not prohibited by
law.
|
It is
impossible for us to state the actual effect it will have on common stock
holders if the board of directors designates a new series of preferred stock.
The effects of such a designation will not be determinable until the rights
accompanying the series have been designated. The issuance of preferred stock
could adversely affect the voting power, liquidation rights or other rights held
by owners of common stock or other series of preferred stock. The board of
directors’ authority to issue preferred stock without stockholder approval could
make it more difficult for a third party to acquire control of our company, and
could discourage any such attempt. We have no present plans to issue any
additional shares of preferred stock.
Series B Preferred Stock
The board
of directors of Focus adopted a Certificate of Designation whereby a total of
3,000 shares of Series B Preferred Stock, $0.01 par value per share are
authorized for issuance. Each share has a liquidation preference in the amount
of $1,190.48 plus all accrued or declared but unpaid dividends, and the holders
of each share of Series B Preferred Stock shall be entitled to receive such
liquidation preference prior to the holders of common stock and Series C
Preferred Stock. Cash dividends on the stock are non-cumulative and are paid at
the option of the board of directors. If paid, the rate shall be seven percent
per annum. The board does not presently intend to pay dividends on the stock. At
the option of the holder, each share is convertible into 1,000 shares of our
common stock. At November 30, 2006, there were 2,744 shares of Series B
Preferred Stock outstanding.
Series
C Preferred Stock
The board
of directors of Focus adopted a Certificate of Designation whereby a total of
500 shares of Series C Preferred Stock, $0.01 par value per share are authorized
for issuance. Each share has a liquidation preference in the amount of $1,560.00
plus all accrued or declared but unpaid dividends, and the holders of each share
of Series C Preferred Stock shall be entitled to receive such liquidation
preference prior to the holders of common stock but not before the holders of
Series B Preferred Stock. Cash dividends on the stock are non-cumulative and are
paid at the option of the board of directors. If paid, the rate shall be seven
percent per annum. The board does not presently intend to pay dividends on the
stock. At the option of the holder, each share is convertible into 1,000 shares
of our common stock. At November 30, 2006, there were 417 shares of Series C
Preferred Stock outstanding.
Options,
Warrants and Notes
As of
November 30, 2006, 5,535,577 options to purchase shares of common stock were
outstanding under our approved stock option plans and 2,956,326 shares of common
stock were available for future grants under our stock option plans. We have
also issued warrants totaling 4,645,395 common stock shares. Holders of options
and warrants do not have any of the rights or privileges of our stockholders,
including voting rights, prior to exercise of the options and warrants. The
number of shares of common stock for which these options and warrants are
exercisable and the exercise price of these options and warrants are subject to
proportional adjustment for stock splits and similar changes affecting our
common stock. Pursuant to the terms of our senior secured convertible notes, we
have reserved an additional 11,443,718 shares of common stock which are issuable
upon their conversion. We have reserved sufficient shares of authorized common
stock to cover the issuance of common stock subject to the options and
warrants.
Limitation
of Liability and Indemnification
Our
second restated certificate of incorporation, as amended, contains provisions
permitted under the General Corporation Law of Delaware relating to the
liability of directors. The provisions provide that our directors will not have
personal liability for monetary damages for any breach of fiduciary duty as a
director, except to the extent that the General Corporation Law of Delaware
prohibits the elimination or limitation of liability of directors for breaches
of fiduciary duty. We also maintain directors’ and officers’ liability
insurance. We believe that these provisions will assist us in attracting and
retaining qualified individuals to serve as directors.
Transfer Agent and Registrar
The
transfer agent and registrar for our common stock is American Stock Transfer and
Trust Company.
NASDAQ
Capital Market
Our
common stock is traded on the NASDAQ Capital Market under the symbol
“FCSE.”
Description
of Our Warrants
We may
issue warrants for the purchase of our common stock. Warrants may be
issued independently or together with our common stock and may be attached to or
separate from any offered securities. Each series of warrants may be
issued under a separate warrant agreement to be entered into between us and a
bank or trust company, as warrant agent. The warrant agent would act
solely as our agent in connection with the warrants. The warrant agent
will not have any obligation or relationship of agency or trust for or with any
holder or beneficial
owners of warrants. This summary of
certain provisions of the warrants is not complete. For the terms of a
particular series of warrants, you should refer to the prospectus supplement for
that series of warrants and the warrant agreement for that particular
series.
The
prospectus supplement relating to a particular series of warrants to purchase
our common stock or preferred stock will describe the terms of the warrants,
including the following:
|
·
the title of the warrants;
|
|
·
the offering price for the warrants, if
any;
|
|
·
the aggregate number of the
warrants;
|
|
·
the designation and terms of the common stock that may be purchased
upon exercise of the warrants;
|
|
·
if applicable, the designation and terms of the securities with
which the warrants are issued and the number of warrants issued with each
security;
|
|
·
if applicable, the date from and after which the warrants and any
securities issued with the warrants will be separately
transferable;
|
|
·
the number of shares of common stock that may be purchased upon
exercise of a warrant and the exercise price for the
warrants;
|
|
·
the dates on which the right to exercise the warrants shall
commence and expire;
|
|
·
if applicable, the minimum or maximum amount of the warrants that
may be exercised at any one time;
|
|
·
the currency or currency units in which the offering price, if any,
and the exercise price are payable;
|
|
·
if applicable, a discussion of material U.S. federal income tax
considerations;
|
|
·
the antidilution provisions of the warrants, if
any;
|
|
·
the redemption or call provisions, if any, applicable to the
warrants;
|
|
·
any provisions with respect to holder’s right to require us to
repurchase the warrants upon a change in control;
and
|
|
·
any additional terms of the warrants, including terms, procedures,
and limitations relating to the exchange, exercise and settlement of the
warrants.
|
Holders
of equity warrants will not be entitled:
|
·
to vote, consent or receive
dividends;
|
|
·
receive notice as stockholders with respect to any meeting of
stockholders for the election or our directors or any other matters;
or
|
|
·
exercise any rights as stockholders of Focus Enhancements,
Inc.
|
Description of Our Units
We may,
from time to time, issue units comprised of one or more of shares of common
stock and warrants that may be offered under this prospectus. Each unit
will be issued so that the holder of the unit is also the holder of each
security included in the unit. Thus, the holder of a unit will have the
rights and obligations of a holder of each included security. The unit
agreement under which a unit is issued may provide that the securities included
in the
unit may not be held or transferred separately at any
time, or at any time before a specified date. This summary of certain provisions
of the units is not complete. For the terms of the units, you should refer
to the prospectus supplement for the units and the unit agreement for that
particular unit.
The
prospectus supplement relating to the units will describe the terms of the
units, including the following:
|
·
the material terms of the securities comprising the units,
including whether and under what circumstances those securities may be
held or transferred separately;
|
|
·
the offering price for the units, if
any;
|
|
·
the aggregate number of the
units;
|
|
·
the designation and terms of the common stock that may be purchased
upon exercise of the warrants comprising the
units;
|
|
·
if applicable, the dates on which the right to exercise the
warrants comprising the units shall commence and
expire;
|
|
·
if applicable, the minimum or maximum amount of the warrants
comprising the units that may be exercised at any one
time;
|
|
·
the currency or currency units in which the offering price, if any,
and the exercise price are payable;
|
|
·
any material provisions relating to the issuance, payment,
settlement, transfer or exchange of the units or of the securities
comprising the units;
|
|
·
if applicable, a discussion of material U.S. federal income tax
considerations;
|
|
·
the antidilution provisions of the units or the securities
comprising the units, if any;
|
|
·
any provisions with respect to holder’s right to require us to
repurchase the units or the securities comprising the units upon a change
in control; and
|
|
·
any additional material provisions of the governing unit
agreement.
|
Manatt,
Phelps & Phillips LLP, Palo Alto, California, will pass upon the validity of
our securities offered by this prospectus.
The
consolidated financial statements as of December 31, 2005 and for the year then
ended, incorporated in this prospectus by reference to the Annual Report on Form
10-K for the year ended December 31, 2005 have been so incorporated in reliance
upon the report (which contains an explanatory paragraph relating to the
Company’s ability to continue as a going concern as described in Note 2 to the
consolidated financial statements) of Burr, Pilger & Mayer LLP, an
independent registered public accounting firm, given on the authority of said
firm as experts in auditing and accounting.
The
consolidated financial statements of Focus as of December 31, 2004 and for each
of the two years in the period ended December 31, 2004, incorporated in this
prospectus by reference from Focus’ Annual Report on Form 10-K for the year
ended December 31, 2005 have been audited by Deloitte & Touche LLP, a
registered independent public accounting firm, as stated in their report (which
report expresses an unqualified opinion and includes an explanatory paragraph
regarding the substantial doubt about Focus’ ability to continue as a going
concern), which is incorporated by reference herein, and have been so
incorporated in reliance upon the report of
such firm given
upon their authority as experts in accounting and auditing.
DISCLOSURE OF COMMISSION
POSITION ON INDEMNIFICATION FOR
SECURITIES ACT LIABILITIES
The Delaware
General Corporation Law and our second restated certificate of incorporation
provide for indemnification of our directors and officers for liabilities and
expenses that they may incur in such capacities. Insofar as
indemnification for liabilities arising under the Securities Act may be
permitted to directors, officers and controlling persons of Focus pursuant to
the foregoing provisions, or otherwise, we have been advised that in the opinion
of the Securities and Exchange Commission such indemnification is against public
policy as expressed in the Securities Act and is, therefore,
unenforceable.
Focus Enhancements (NASDAQ:FCSE)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Focus Enhancements (NASDAQ:FCSE)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024